Patient availability is often overestimated during trial planning. This usually starts at feasibility, where sites are asked to report how many patients they ha...
Continue reading
Trial sponsors often assume that site enablement is largely complete once a trial launches. Feasibility assessments, training materials, and startup timelines a...
Continue reading
Recruitment for genetically stratified clinical trials is a critical bottleneck for sponsors. Identifying individuals with specific variants, building trust aro...
Continue reading
Participation in clinical trials can be burdensome and disruptive. In addition to practical inconveniences and discomfort, participants may have to take time of...
Continue reading
Study start-up is a critical stage of the drug development process and can have a major impact on trial timelines, budgets, and overall success. Start-up activi...
Continue reading
At the Partnerships with Sites summit in September 2025, new data from the Tufts Center for the Study of Drug Development (Tufts CSDD) underscored how the globa...
Continue reading
Advocating for patients is one of the core pillars of Sano’s mission. Our approach to clinical trials is patient-centered and entails deep and meaningful engage...
Continue reading
At this year’s DPHARM conference, Sano’s VP of Commercial, Ben Jackson, joined a panel on clinical trial patient matching moderated by a clinical expert from No...
Continue reading
The next generation of advanced therapies, particularly gene therapies, hold enormous promise for patients with rare conditions. However, their clinical develop...
Continue reading
In recent years, the therapeutic landscape for genetic hearing loss (GHL) has advanced rapidly, with several programs reaching clinical development. However, tr...
Continue reading